Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio

European Urology

Volumn 45, Issue 2, 2004, Pages 160-165

  Aus, Gunnar ^a   Becker, Charlotte ^b   Franzén, Stefan ^a   Lilja, Hans ^c,d   Lodding, Pär ^a   Hugosson, Jonas ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Diagnosis; Free to total PSA; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; STATISTICAL SIGNIFICANCE;

EID: 0742306801     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2003.09.008     Document Type: Article

References (16)

1. Bray F., Sankila R., Ferlay J., Parkin D.M. Estimates of cancer incidence and mortality in Europe in 1995. Eur. J. Cancer. 38:2002;99-166.
2. Black R.J., Bray F., Ferlay J., Parkin D.M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur. J. Cancer. 33:1997;1075-1107.
3. Bangma C.H., Kranse R., Blijenberg B.G., Schroeder F.H. The value of screening tests in the detection of prostate cancer. Part 1: Results of a retrospective evaluation of 1726 men. Urology. 46:1995;773-778.
4. Catalona W.J., Ritchie J.P., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C.et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer. Results of a multicenter clinical trial of 6630 men. J. Urol. 151:1994;1283-1290.
5. Kranse R., Beemsterboer P., Rietbergen J., Habbema D., Hugosson J., Schröder F.H. Predictors for biopsy outcome in the European Randomized study of screening for prostate cancer (Rotterdam region). Prostate. 39:1999;316-322.
6. Christensson A., Bjork T., Nosson O., Dahlen U., Matikainen M.T., Cockett A.T.et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypson as an indicator for prostate cancer. J. Urol. 150:1993;100-105.
7. Abrahamsson P.A., Lilja H., Oesterling J.E. Molecular forms of serum prostate specific antigen. The clinical value of percent free prostate specific antigen. Urol. Clin. North Am. 24:1997;353-365.
8. Mitrunen K., Pettersson K., Piironen T., Björk T., Lilja H., Lövgren T. Dual-label one step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin. Chem. 41:1995;1115-1120.
9. Aus G., Bergdahl S., Hugosson J., Lodding P., Pihl C.G., Pileblad E. Outcome of laterally directed sextant biopsies of the prostate in screened males aged 50-66 years. Implications for sampling order. Eur. Urol. 39:2001;655-660.
10. Marubini E, Valsechi MG. Analysing survival data from clinical trials and observational studies. Chichester (England): Wiley-Liss; 1995.
11. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A.et al. Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 279:1998;1542-1547.
12. Finne P., Auvinen A., Aro J., Juusela H., Maattanen L., Rannikko S.et al. Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur. Urol. 41:2002;619-627.
13. Roehl K.A., Antenor J.A.V., Catalona W.J. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4. ng/ml range J. Urol. 168:2002;922-925.
14. Smith D.S., Catalona W.J., Herschman J.D. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 276:1996;299-300.
15. de la Taille A., Houlgatte A., Houdelette P., Goluboff E.T., Berlizot P., Ricordel I. Influence of free-to-total prostate specific antigen variability in the early diagnosis of prostate cancer: a comparative study of three immunoassays. Br. J. Urol. 82:1998;389-392.
16. Stephan C., Cammann H., Semjonov A., Diamandis E.P., Wymenga L.F., Sinha P.et al. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unneccessary biopsies. Clin. Chem. 48:2002;1279-1287.